Aggressiveness From New biomarkers can be predictedScientists at the University of California, San Diego and the Moores UCSD Cancer Center have evidence of a potential new biomarker for the aggressiveness of an often to-treat form to-treat form of leukemia. They found that high levels of a certain enzyme in the blood is an indicator that chronic lymphocytic leukemia are – the most common form of adult leukemia – will be aggressive and need immediate treatment.
‘In some cases, where. The level of expression PDE7B prognostic information that was additive to existing markers’.
Zhang said that PDE7B can as a biomarker for as a biomarker for CLL if the enough enough, but may be used with other markers if the level is lower and ambiguous. PDE7B may not be good enough by itself, if it is not high enough, she noted. If it is low, other markers could be helpful. .
The American Cancer Society estimates that in 2008 approximately 15,100 new cases of CLL occurred in the United States, with about 4,400 deaths from the disease.Other UCSD authors include: Laura Rassenti, Minya Pu, Fiona Murray, Joan Kanter, Andrew Greaves and Karen Messer.S. Population is either overweight or clinically obese. Over – consumption, or binge eating, of high levels of fats, carbohydrates and sugar, according to some researchers, are largely responsible for this epidemic..A natural ability regulate blood sugar levels and persons with type 1 diabetes, their lives back together has Pursuing a Cure for Type 1 diabetes stays which largest interest in and commitment in my career, I see a big pledge in the of these scientific and corporate cooperation in order to achieve of a definitive treating of this difficult disease, ‘said Alexander ‘Zan ‘Fleming, the management diabetes medicine verification in FDA and now serves as Chief Medical Officer of Kinexum Metabolics..
On DiaKineDiaKine Therapeutics, is a development Stage company commercialization of new immunomodulators in. Targeting treating autoimmunity and inflammatory conditions such as diabetes and complications. Of these new drug regulating cytokines, part of the endogenous wrongly mistakenly attack tissue and inflammation. The company is developing its first product, IsletLife LSF Media 1, the viability and harvesting insulin -producing islet cells of to enhance abilities before transplant. IsletLife LSF Material 1thus potentially improving the success quota the procedure. For more therapeutic the development on DiaKine belong: stop adjunctive treatment to their cell transplantation island of, the progression of the Type of require 1 diabetes of newly diagnosed adults, treating and preventing phase change Auto Immune diabetic of adults , treating and prevention of insulin type 2 diabetic, Treat and prevent diabetes complications.
About Kinexum Metabolics,Kinexum Metabolics has on on developing therapies for treating type 1 or type – 2 diabetic and others metabolic illnesses focus.